Immunosuppression for adult steroid-dependent or frequently relapsing nephrotic syndrome: A systematic review and meta-analysis
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0307981 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS ONE, 2024. Verfasst von Zhi Yong Wong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Nephrotic Syndrome, Immunosuppressive Agents. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
There is limited evidence on which immunosuppressive agents produce the best outcomes for adult patients with steroid-dependent or frequently relapsing nephrotic syndrome (SDNS/FRNS). This review compares the remission rate and adverse effects of various immunosuppressants used.
Methods
Studies of adult patients with biopsy-proven SDNS/FRNS, administered any immunosuppressive agents and reported complete remission results as one of the clinical outcomes were included. Articles were independently screened by two researchers. ROBINS-I was used for risk of bias assessment. Random-effects model was used for statistical analysis and corresponding 95% confidence intervals (CIs) were calculated.
Results
574 patients across 28 studies were included in the analysis. Patients receiving rituximab have a complete remission rate of 89% (95% CI = 83% to 94%; τ2 = 0.0070; I2 = 62%; overall p < 0.01, low certainty) and adverse event rate of 0.26, cyclosporine (CR 40%; 95% CI = 21% to 59%; τ2 = 0.0205; I2 = 55%; overall p = 0.08, low certainty), tacrolimus (CR 84%; 95% CI = 70% to 98%; τ2 = 0.0060; I2 = 33%; overall p = 0.21, moderate certainty), mycophenolate mofetil (CR 82%; 95% CI = 74% to 90%; τ2 < 0.0001; I2 = 15%; overall p = 0.32, moderate certainty) and cyclophosphamide (CR 79%; 95% CI = 69% to 89%; τ2 = 0; I2 = 0%; overall p = 0.52, moderate certainty).
Conclusion
Among the commonly used immunosuppressive agents, only rituximab has a statistically significant effect in achieving complete remission among patients with SDNS/FRNS and has a relatively good safety profile, but this is limited by low quality of evidence with high degree of heterogeneity causing a lack of statistical power.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
- Faculty of Medicine, Department of Anesthesiology, University of Malaya, Kuala Lumpur, Malaysia.
- Faculty of Medicine, Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
ORCID-Profile: Zhi Yong Wong, Chiu Yee Teo, Soo Kun Lim
Zitieren
APA
Wong, Z. Y., Teo, C. Y., Fiona Wong, Y. Q., Ng, K. T., & Lim, S. K. (2024). Immunosuppression for adult steroid-dependent or frequently relapsing nephrotic syndrome: A systematic review and meta-analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0307981
Vancouver
Wong ZY, Teo CY, Fiona Wong YQ, Ng KT, Lim SK. Immunosuppression for adult steroid-dependent or frequently relapsing nephrotic syndrome: A systematic review and meta-analysis. PLOS ONE. 2024. doi:10.1371/journal.pone.0307981
BibTeX
@article{Wong2024,
author = {Wong, Zhi Yong and Teo, Chiu Yee and Fiona Wong, Yan Qi and Ng, Ka Ting and Lim, Soo Kun},
title = {Immunosuppression for adult steroid-dependent or frequently relapsing nephrotic syndrome: A systematic review and meta-analysis},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0307981}
}
EUVIMED